Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03132922 · OUTCOME

Peak Persistence

MAGE-A4ᶜ¹º³²T for Multi-Tumor · Source last updated 2026-06-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
DNA copies/microgram
Interval / dispersion
Standard Deviation
Time frame
From afamitresgene autoleucel infusion up to 18 months post-infusion

What was measured

Peak persistence of afamitresgene autoleucel cells was reported as vector copy numbers per microgram of genomic DNA from peripheral blood mononuclear cell (PBMC).

Analysis population: Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel and had a post-infusion sample tested for persistence

Groups in this outcome

Afamitresgene Autoleucel, Group 1

Participants who received afamitresgene autoleucel 0.1x10\^9 transduced cells

Afamitresgene Autoleucel, Group 2

Participants who received afamitresgene autoleucel 0.5-1.2x10\^9 transduced cells

Afamitresgene Autoleucel Group 3 + Expansion

Participants who received afamitresgene autoleucel 1.2-10x10\^9 transduced cells

Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel

Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion (1.2-10x10\^9 transduced cells).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Afamitresgene Autoleucel, Group 13
Afamitresgene Autoleucel, Group 23
Afamitresgene Autoleucel Group 3 + Expansion32
Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel4

Reported measurements

Source class 1
Values in DNA copies/microgram · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Afamitresgene Autoleucel, Group 110766.2312504.705Not reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 288900.2653873.432Not reportedNot reportedNot reported
Afamitresgene Autoleucel Group 3 + Expansion165035.8999806.129Not reportedNot reportedNot reported
Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel185,532.5800116322.7494Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        12504.705
        value
        10766.23
      2. group Id
        OG001
        spread
        53873.432
        value
        88900.26
      3. group Id
        OG002
        spread
        99806.129
        value
        165035.89
      4. group Id
        OG003
        spread
        116322.7494
        value
        185,532.5800
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      32
    4. group Id
      OG003
      value
      4
    units
    Participants
description
Peak persistence of afamitresgene autoleucel cells was reported as vector copy numbers per microgram of genomic DNA from peripheral blood mononuclear cell (PBMC).
dispersion Type
Standard Deviation
groups
  1. description
    Participants who received afamitresgene autoleucel 0.1x10\^9 transduced cells
    id
    OG000
    title
    Afamitresgene Autoleucel, Group 1
  2. description
    Participants who received afamitresgene autoleucel 0.5-1.2x10\^9 transduced cells
    id
    OG001
    title
    Afamitresgene Autoleucel, Group 2
  3. description
    Participants who received afamitresgene autoleucel 1.2-10x10\^9 transduced cells
    id
    OG002
    title
    Afamitresgene Autoleucel Group 3 + Expansion
  4. description
    Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion (1.2-10x10\^9 transduced cells).
    id
    OG003
    title
    Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel
param Type
MEAN
population Description
Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel and had a post-infusion sample tested for persistence
reporting Status
POSTED
time Frame
From afamitresgene autoleucel infusion up to 18 months post-infusion
title
Peak Persistence
type
PRIMARY
unit Of Measure
DNA copies/microgram

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice